Ozempic maker Novo Nordisk says its highly anticipated experimental weight-loss pill Amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
The company, the maker of blockbuster drugs Wegovy and Ozempic, said in March that a phase-one trial of the pill version of Amycretin showed participants lost up to 13.1 per cent of their weight after 12 weeks. That compared to weight loss of about 6 per cent after 12 weeks and 15 per cent after 68 weeks in trials of Wegovy.
